The data supports ACI-24's safety and immunogenicity but highlights the need for improved antibody response. Monitor Cohort AD4 results for enhanced immunogenicity and any future Takeda option exercise decision. The stock may remain range-bound until more definitive efficacy data emerges.
Price Chart
Executive Summary
AC Immune reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease. The therapy was generally safe with no ARIA-E and showed anti-Abeta antibody dose responses, but immunogenicity may be suboptimal, prompting the initiation of Cohort AD4 with an additional adjuvant. The Takeda partnership milestone of $12M was achieved, but the data lacks efficacy endpoints and the need for enhanced immunogenicity tempers the outlook.
Key Facts
- Interim data from 74 patients in first three cohorts (AD1-3) after 12 months of ACI-24 treatment
- ACI-24 generally safe and well tolerated with no evidence of ARIA-E
- Anti-Abeta antibody responses detected at every dose level with dose response
- Cohort AD4 initiated with an additional adjuvant to enhance immunogenicity
- Takeda agreement includes $100M upfront payment and $12M milestone achieved on dosing first patients in Cohort AD4
Financial Impact
Takeda milestone of $12M achieved; potential future milestones up to ~$2.1B plus tiered double-digit royalties, but no near-term revenue impact
Risk Factors
- Immunogenicity may still be insufficient for meaningful plaque removal even with adjuvant
- No efficacy data (plaque reduction or cognitive endpoints) reported yet
- Competition from approved anti-amyloid antibodies (e.g., lecanemab) could limit commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.41 (−1.63%) |
Oct 9, 2026 17d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.41 (−3.60%) |
Oct 2, 2026 24d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.41 (−11.56%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.41 (−14.84%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.41 (−17.75%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.41 (−8.71%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.41 (−8.71%) |
Aug 11, 2026 10w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.41 (−5.12%) |
Aug 11, 2026 10w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.41 (−5.12%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.41 (+5.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers